Abstract
Introduction Understanding the holistic impact of malaria during pregnancy is essential for improving maternal and child outcomes in malaria endemic settings. To be able to design appropriate research and conduct robust policy analyses, a comprehensive model of the underlying disease, representing the current understanding of mechanisms and consequences is essential. This study aimed to illustrate a methodology to co-develop a disease model with expert stakeholders using malaria during pregnancy as a case study.
Methods An initial steering group was convened to develop a first model of malaria during pregnancy and its consequences for mother and child based on their understanding of the literature. Subsequently, this model was refined using a Delphi process to gain consensus amongst twelve experts, representing the disciplines of health economics, mathematical modelling, epidemiology and clinical medicine, working in the field of malaria during pregnancy. Experts reviewed drafts of the conceptual model and provided feedback in two rounds of semi-structured questionnaires with the aim of identifying the most important health outcomes and relationships in both mother and child as well as the most relevant stratifiers for the model. Consensus on any final disagreement was reached after two consensus meetings.
Results The final model is a comprehensive disease model of malaria during pregnancy, including ten maternal and ten child outcomes with four stratifiers. The model developed in this study should be of value to malaria researchers, funders, evaluators and decision makers, though some adaptation will be required for each specific context and purpose. In addition, the methodology and process followed in this study is replicable and can guide researchers aiming to develop a conceptual model for other conditions.
Discussion & Conclusion The model resulting from this study highlights the complexity required to depict appropriately the consequences of malaria during pregnancy for both the mother and the child. It also demonstrates how to conduct a rigorous process to develop a disease model. In addition the study has helped to identify a number of areas with scarce data and need for further research.
Funding This study from part of the IMPROVE and IMPROVE-2 studies, which received financial support from the EDCTP2 programme under Horizon 2020 (TRIA.2015-1076, TRIA.2015-1076b); the UK Department of Health and Social Care, the UK Foreign Commonwealth and Development Office, the UK Medical Research Council, and Wellcome Trust, through the Joint Global Health Trials scheme (MR/P006922/1); and the Swedish International Development Cooperation Agency.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study forms part of the PhD of SF supervised by KH, with an aim to be used in the cost-effectiveness analysis of the IMPROVE (TRIA.2015-1076) and IMPROVE-2 (TRIA.2015-1076b) trials. SF was funded on both IMPROVE trials to conduct the cost-effectiveness analysis into which this conceptual model will feed. The study received financial support from the EDCTP2 programme under Horizon 2020 (TRIA.2015-1076, TRIA.2015-1076b) the UK Department of Health and Social Care, the UK Foreign Commonwealth and Development Office, the UK Medical Research Council, and Wellcome Trust, through the Joint Global Health Trials scheme (MR/P006922/1) and the Swedish International Development Cooperation Agency.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for this study was received on 12 July 2022 by the Research Ethics Committee of the London School of Hygiene and Tropical Medicine (Reference number 27361).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
Due to the small size of the Delphi panel, the detailed data collected during the Delphi consultations cannot be made available as individuals participating in the Delphi panel can be easily identified. However, a detailed analysis report, with all identifying information removed has been submitted for both rounds of Delphi consultations as an appendix.
Abbreviations:
- CEA
- Cost effectiveness analysis
- DALY
- disability-adjusted life years
